Based on Clarity's multi-model valuation engine, Jazz Pharmaceuticals plc (JAZZ) has an estimated fair value of $360.97 per share, compared to its current market price of $182.01. The stock is currently trading 98.3% below Clarity's fair value estimate, resulting in a verdict of SIGNIFICANTLY UNDERVALUED.

This valuation blends 2 independent models — including EV/Revenue, Discounted Cash Flow (DCF). The primary weight is given to the EV/Revenue model, with Bayesian triangulation used to reconcile the estimates into a single blended fair value. The 2 models show high agreement with a 4% spread between the highest and lowest estimates.

Monte Carlo simulation across 5,000 scenarios estimates a 100% probability that the stock is trading below its intrinsic value, with a median simulated value of $355.51.

Clarity's 1-year price target is $495.17, reflecting expected earnings growth and margin trajectory.

Jazz Pharmaceuticals plc is classified under the Pharma / Biotech sector, and this valuation is based on 10-K · Filed 2026-02-24 filings sourced directly from SEC EDGAR. All models use trailing twelve month (TTM) financials where available, with sector-appropriate growth and discount rate assumptions.